CLOS
ENTA icon

Compagnie Lombard Odier SCmA’s Enanta Pharmaceuticals ENTA Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-42,000
Closed -$1.51M – 693
2017
Q2 		$1.51M Buy
+42,000
New +$1.34M 0.05% 193

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Compagnie Lombard Odier SCmA's ENTA Position: Q3 2017 in Review

Compagnie Lombard Odier SCmA sold out of Enanta Pharmaceuticals (ENTA) in Q3 2017, closing a stake of 42,000 shares — an estimated $1.51M sold.

Compagnie Lombard Odier SCmA first reported a position in ENTA in Q2 2017 and held it in 1 quarter. The position peaked at $1.51M in Q2 2017. 127 funds tracked by Wall St. Rank hold ENTA as of Q3 2017.

  • Compagnie Lombard Odier SCmA reported no remaining Enanta Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 42,000 Enanta Pharmaceuticals shares in Q3 2017, an estimated $1.51M.
  • Compagnie Lombard Odier SCmA first reported a position in Enanta Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Compagnie Lombard Odier SCmA's Enanta Pharmaceuticals position peaked at $1.51M in Q2 2017.
  • 127 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2017.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q3 2017, filed 14 Nov 2017.